

FoI request re: Biologic treatment in dermatology Ref: 20-JJ-1910

Thank you for your request for information relating to the number of patients treated in the last 3 months by the Dermatology department.

This was received on 21 September 2020 and has been dealt with under the terms of the Freedom of Information Act 2000.

Please find our responses below:

Request 1:

Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs?

Adalimumab - Humira	0
Adalimumab Biosimilar	≤5
Apremilast	N/A
Brodalumab	0
Certolizumab	0
Dimethyl fumarate	0
Etanercept - Enbrel	0
Etanercept Biosimilar	0
Guselkumab	≤5
Infliximab - Remicade	0
Infliximab Biosimilar	≤5
Ixekizumab	≤5
Risankizumab	≤5
Secukinumab	≤5
Tildrakizumab	0
Ustekinumab	12

Please note that the trust's policy is not to provide patient or staff numbers, where the response is less than or equal to five (\leq 5) as it would potentially allow identification of the individual patient/staff and would therefore be personal data. The trust considers that release of that information would breach GDPR/DPA18 principles on the grounds that it would not be fair in all the circumstances. This information is therefore exempt under section 40 of the FOI Act 2000.

Request 2:

For the patients treated by the Dermatology department in the last three months with any of the above drugs, can you please provide the total number of paediatric (up to age 16) versus adult patients?

We do not hold this information as age is not recorded on stock control system.

Request 3:

Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs?

Whittington Health NHS Trust



Chair: Baroness Julia Neuberger Chief Executive: Siobhan Harrington





Adalimumab - Humira	≤5
Adalimumab Biosimilar	8
Golimumab	0
Infliximab - Remicade	≤5
Infliximab Biosimilar	30
Tofacitinib	N/A
Ustekinumab	10
Vedolizumab	11

Please note that the trust's policy is not to provide patient or staff numbers, where the response is less than or equal to five (\leq 5) as it would potentially allow identification of the individual patient/staff and would therefore be personal data. The trust considers that release of that information would breach GDPR/DPA18 principles on the grounds that it would not be fair in all the circumstances. This information is therefore exempt under section 40 of the FOI Act 2000.

I hope you find this information useful. Please quote the above reference in any further communication on this matter.

If you require any further assistance, please do not hesitate to contact me by email or at the address shown below.

Yours sincerely

FOI Coordinator **Freedom of Information Office** Whittington Health Highgate Wing, Level 5 Magdala Avenue London, N19 5NF <u>foi.whitthealth@nhs.net</u>

Whittington Health

If you are dissatisfied with this response, Whittington Health operates a complaints procedure, details of which can be found below: **FOI Complaints:** If you remain dissatisfied with the Trust's response, you In the first instance, write to: may write to: **Director Lead for Information Information Commissioner's Office** Governance Wycliffe House Water Lane Chief Operating Officer Jenner Building Wilmslow Cheshire SK9 5AF Magdala Avenue Telephone: 0303 123 1113 or 01625 545745 London N19 5NF www.ico.org.uk 020 7288 5255

Whittington Health NHS Trust



Chief Executive: Siobhan Harrington





Helping local people live longer healthier lives



foi.whitthealth@nhs.net

Whittington Health NHS Trust

Chair: Baroness Julia Neuberger Chief Executive: Siobhan Harrington



